NCT00263679View on ClinicalTrials.gov

Assessment of GSK Biologicals' Tdap Candidate Vaccine Administered as a Booster (6th Dose) in Terms of Immunogenicity and Safety to Children and Adolescents Previously Vaccinated With Five Doses of an Acellular Pertussis-containing Vaccine.

PHASE3CompletedINTERVENTIONAL
Enrollment

321

Participants

Timeline

Start Date

November 30, 2003

Primary Completion Date

May 31, 2004

Study Completion Date

October 31, 2004

Conditions
Acellular PertussisDiphtheriaTetanus
Interventions
BIOLOGICAL

Prophylaxis: Diphtheria, tetanus and pertussis

Trial Locations (13)

24937

GSK Investigational Site, Flensburg

24939

GSK Investigational Site, Flensburg

24943

GSK Investigational Site, Flensburg

24944

GSK Investigational Site, Flensburg

25813

GSK Investigational Site, Husum

40699

GSK Investigational Site, Erkrath

47798

GSK Investigational Site, Krefeld

47877

GSK Investigational Site, Willich

54290

GSK Investigational Site, Trier

55131

GSK Investigational Site, Mainz

65549

GSK Investigational Site, Limburg an der Lahn

77694

GSK Investigational Site, Kehl

77704

GSK Investigational Site, Oberkirch

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00263679 - Assessment of GSK Biologicals' Tdap Candidate Vaccine Administered as a Booster (6th Dose) in Terms of Immunogenicity and Safety to Children and Adolescents Previously Vaccinated With Five Doses of an Acellular Pertussis-containing Vaccine. | Biotech Hunter | Biotech Hunter